Table 2. . Antimicrobial susceptibility profiles of 28 Mycobacterium abscessus clinical strains against carbapenems (with and without avibactam, 4 µg/ml) and antibacterials that are currently used to treat M. abscessus infection and where available currently used Clinical Laboratory Standard Institute breakpoints for interpretation.
| M. abscessus clinical strain |
MIC of carbapenems with and without avibactam |
Susceptibility profile for antibacterials used for treatment of M. abscessus infections |
Avi | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erta | Erta + Avi | Mero | Mero + Avi | Imi | Imi + Avi | Dori | Dori + Avi | Bia | Bia + Avi | Faro | Faro + Avi | Tebi | Tebi + Avi | Pani | Pani + Avi | CLR | SXT | CIP | MOX | FOX | AMI | LZD | IMI | TOB | TGC | KAN | ||
| 1N |
128 |
16 |
16 |
4 |
8 |
8 |
16 |
4 |
16 |
4 |
64 |
32 |
256 |
4 |
128 |
16 |
I |
R |
R |
R |
I |
R |
R |
I |
R |
4 |
8 |
>256 |
| 2N |
256 |
8 |
8 |
4 |
8 |
8 |
16 |
8 |
16 |
4 |
128 |
32 |
256 |
8 |
64 |
8 |
R |
R |
R |
R |
I |
S |
R |
I |
R |
0.5 |
16 |
>256 |
| 3N |
128 |
16 |
16 |
4 |
8 |
8 |
32 |
4 |
16 |
4 |
64 |
32 |
256 |
4 |
64 |
16 |
R |
ND |
ND |
R |
I |
ND |
R |
I |
ND |
ND |
16 |
>256 |
| 4N |
64 |
16 |
16 |
8 |
16 |
16 |
16 |
8 |
16 |
8 |
64 |
16 |
256 |
4 |
32 |
16 |
R |
R |
R |
R |
I |
R |
R |
I |
R |
1 |
8 |
>256 |
| 5N |
64 |
16 |
16 |
4 |
32 |
32 |
16 |
4 |
16 |
8 |
64 |
16 |
256 |
8 |
128 |
32 |
I |
R |
R |
R |
I |
R |
R |
R |
R |
1 |
16 |
>256 |
| 6N |
128 |
16 |
16 |
4 |
8 |
8 |
16 |
4 |
16 |
4 |
128 |
32 |
256 |
4 |
128 |
8 |
R |
ND |
ND |
R |
I |
ND |
R |
I |
ND |
ND |
16 |
>256 |
| 11N |
>256 |
32 |
128 |
8 |
32 |
32 |
128 |
8 |
128 |
8 |
128 |
64 |
>256 |
16 |
128 |
64 |
R |
R |
R |
R |
I |
R |
R |
R |
R |
4 |
>256 |
>256 |
| 12N |
>256 |
16 |
16 |
4 |
16 |
8 |
32 |
4 |
16 |
4 |
128 |
32 |
>256 |
4 |
128 |
16 |
R |
S |
R |
R |
I |
S |
R |
I |
R |
0.25 |
16 |
>256 |
| 13N |
256 |
8 |
32 |
8 |
32 |
16 |
16 |
8 |
16 |
8 |
64 |
32 |
128 |
8 |
64 |
16 |
S |
R |
R |
R |
S |
S |
I |
R |
R |
1 |
8 |
>256 |
| 14N |
>256 |
32 |
128 |
8 |
32 |
8 |
32 |
8 |
64 |
8 |
128 |
64 |
>256 |
16 |
256 |
32 |
I |
R |
R |
R |
I |
S |
R |
R |
R |
4 |
16 |
>256 |
| 19N |
256 |
8 |
16 |
4 |
4 |
4 |
16 |
4 |
16 |
4 |
128 |
32 |
128 |
4 |
64 |
4 |
R |
R |
R |
R |
I |
S |
R |
S |
R |
1 |
8 |
>256 |
| 201 |
256 |
16 |
32 |
4 |
16 |
8 |
32 |
4 |
32 |
8 |
256 |
64 |
>256 |
4 |
128 |
8 |
R |
R |
R |
R |
I |
R |
R |
I |
R |
4 |
16 |
>256 |
| 202 |
>256 |
32 |
128 |
8 |
32 |
8 |
64 |
8 |
128 |
8 |
128 |
64 |
>256 |
8 |
256 |
16 |
R |
R |
R |
R |
I |
R |
R |
R |
R |
1 |
16 |
>256 |
| 203 |
>256 |
32 |
64 |
8 |
16 |
16 |
64 |
8 |
64 |
8 |
128 |
32 |
128 |
8 |
64 |
16 |
R |
R |
R |
R |
I |
R |
R |
I |
R |
2 |
64 |
>256 |
| 204 |
>256 |
32 |
128 |
8 |
32 |
16 |
128 |
8 |
64 |
16 |
256 |
64 |
>256 |
8 |
256 |
16 |
R |
R |
R |
R |
I |
S |
R |
R |
R |
4 |
32 |
>256 |
| 206 |
>256 |
16 |
32 |
4 |
16 |
8 |
32 |
8 |
32 |
8 |
128 |
32 |
256 |
4 |
128 |
8 |
I |
R |
R |
R |
I |
S |
R |
I |
R |
0.5 |
32 |
>256 |
| 208 |
256 |
16 |
16 |
4 |
16 |
8 |
32 |
8 |
16 |
8 |
64 |
32 |
256 |
4 |
64 |
8 |
R |
R |
R |
R |
I |
R |
R |
I |
R |
0.5 |
32 |
>256 |
| 210 |
256 |
8 |
16 |
8 |
8 |
8 |
32 |
4 |
32 |
8 |
128 |
32 |
256 |
8 |
64 |
8 |
R |
R |
R |
R |
I |
R |
R |
S |
R |
1 |
32 |
>256 |
| 211 |
>256 |
16 |
32 |
4 |
16 |
8 |
32 |
4 |
16 |
4 |
128 |
64 |
>256 |
4 |
64 |
16 |
R |
R |
R |
R |
I |
R |
R |
I |
R |
0.5 |
16 |
>256 |
| 212 |
>256 |
32 |
16 |
8 |
16 |
8 |
16 |
8 |
16 |
8 |
64 |
32 |
256 |
8 |
64 |
16 |
R |
R |
R |
R |
I |
R |
R |
I |
R |
0.5 |
16 |
>256 |
| 214 |
64 |
16 |
16 |
8 |
32 |
32 |
8 |
4 |
16 |
8 |
64 |
16 |
128 |
8 |
64 |
32 |
S |
R |
R |
R |
S |
R |
R |
R |
R |
1 |
16 |
>256 |
| 215 |
64 |
8 |
16 |
8 |
32 |
32 |
16 |
8 |
16 |
8 |
64 |
16 |
256 |
16 |
64 |
32 |
R |
R |
R |
R |
I |
R |
R |
R |
R |
2 |
32 |
>256 |
| 216 |
128 |
16 |
16 |
8 |
16 |
16 |
16 |
8 |
32 |
8 |
128 |
64 |
256 |
16 |
64 |
16 |
R |
R |
R |
R |
I |
R |
R |
I |
R |
1 |
8 |
>256 |
| 218 |
128 |
16 |
16 |
4 |
8 |
8 |
8 |
4 |
16 |
8 |
64 |
32 |
256 |
8 |
32 |
16 |
R |
R |
S |
R |
I |
S |
R |
I |
R |
1 |
8 |
>256 |
| JHH2 |
>256 |
32 |
128 |
8 |
16 |
16 |
32 |
8 |
32 |
8 |
256 |
64 |
>256 |
16 |
256 |
16 |
R |
ND |
R |
R |
I |
I |
R |
I |
R |
≤4 |
>256 |
>256 |
| JHH4 |
128 |
16 |
16 |
4 |
16 |
8 |
16 |
4 |
16 |
8 |
64 |
32 |
256 |
8 |
64 |
16 |
R |
ND |
R |
R |
I |
R |
R |
I |
R |
>4 |
16 |
>256 |
| JHH9 |
128 |
8 |
16 |
4 |
16 |
8 |
16 |
4 |
16 |
4 |
64 |
32 |
256 |
4 |
64 |
16 |
R |
ND |
R |
R |
I |
R |
R |
I |
R |
>4 |
16 |
>256 |
| JHHKB | >256 | 64 | 128 | 16 | 32 | 16 | 128 | 8 | 128 | 16 | 64 | 32 | 128 | 16 | 256 | 32 | R | ND | ND | R | I | ND | R | R | ND | ND | >256 | >256 |
AMI: Amikacin (susceptible, 1–16 µg/ml, intermediate: 32 µg/ml, resistant: ≥64 µg/ml); Avi: Avibactam; Bia: Biapenem; CIP: Ciprofloxacin (susceptible: 0.12–1 µg/ml, intermediate: 2 µg/ml, resistant: ≥4 µg/ml); CLR: Clarithromycin (susceptible: 0.06–2 µg/ml, intermediate: 4 µg/ml, resistant: ≥8 µg/ml); Dori: Doripenem; Erta: Ertapenem; Faro: Faropenem; FOX: Cefoxitin (susceptible, 4–16 µg/ml, intermediate: 32–64 µg/ml, resistant: ≥128 µg/ml); I: Intermediate; Imi or IMI: Imipenem (susceptible, 2–4 µg/ml, intermediate: 8–16 µg/ml, resistant: ≥32 µg/ml); KAN: Kanamycin (no interpretation for this drug currently available, however, an MIC >5 µg/ml for M. tuberculosis is considered resistant in broth; LZD: Linezolid (susceptible: 1–8 µg/ml, intermediate: 16 µg/ml, resistant: ≥32 µg/ml); Mero: Meropenem; MXF: Moxifloxacin (susceptible: 0.25–1 µg/ml, intermediate: 2 µg/ml, resistant: ≥4 µg/ml); ND: Not determined; Pani: Panipenem; R: Resistant; S: Susceptible; SXT: Trimethoprim/sulfamethoxazole (susceptible: 0.25/4.75–2/38 µg/ml, resistant: ≥4/76 µg/ml); Tebi: Tebipenem; TGC: Tigecycline (no interpretation for this drug currently available, however an MIC >4 µg/ml for M. tuberculosis is considered resistant in broth); TOB: Tobramycin (susceptible, 1–2 µg/ml, intermediate: 4 µg/ml, resistant: ≥8 µg/ml).
S, I and R are classifications based on CLSI breakpoints.